Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Stock Information for Vaccinex Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vaccinex Inc.

Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Vaccinex, Inc. Announces Reverse Stock Split
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.